Sagimet Biosciences (SGMT) Q3 2026 earnings summary

Executive summary

• First patient dosed in the registrational U.S. AURORA Phase 3 trial of denifanstat for moderate to severe acne; topline data expected in H2 2027.

• October financing lifted pro forma cash to $355.8M, expected to fund operations through mid-2029, including the AURORA readout and potential NDA submission.

Financial highlights

• Q3 R&D expense rose 68% YoY to $16.3M from $9.7M, largely reflecting denifanstat acne Phase 3 activity and manufacturing.

• Q3 G&A expense was $5.2M versus $4.6M; total operating expenses were $21.6M versus $14.3M.

• Q3 net loss was $19.1M versus $12.9M; 9M net loss was $43.8M versus $41.5M.

• 9M operating cash use was $31.8M versus $33.8M; cash and cash equivalents were $111.0M at September 30.

Outlook and guidance

• AURORA plans to enroll ~800 U.S. patients aged 12 and older, including ~450 adolescents; denifanstat 50 mg versus placebo will be assessed over 12 weeks.

• TVB-3567 Phase 2 in moderate to severe acne is expected to start by year-end 2026; development of a topical FASN inhibitor will continue.

• FDA consultation on a denifanstat-resmetirom MASH Phase 2 design is anticipated in Q1 2027; further MASH clinical development awaits non-dilutive financing.